Compare JOB & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOB | CASI |
|---|---|---|
| Founded | 1893 | 1991 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 19.7M |
| IPO Year | N/A | 1996 |
| Metric | JOB | CASI |
|---|---|---|
| Price | $0.23 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 432.2K | 38.0K |
| Earning Date | 02-12-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,504,000.00 | $26,846,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.72 |
| 52 Week Low | $0.17 | $0.75 |
| 52 Week High | $0.27 | $3.09 |
| Indicator | JOB | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 35.20 |
| Support Level | $0.23 | $0.81 |
| Resistance Level | $0.24 | $0.98 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 11.38 | 4.26 |
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.